BBlogFlow

John Stamos Addresses Mike Love’s Health as Beach Boys Concert Footage Raises Concerns: ‘We Don’t Know What the Future Holds — We Have Tonight’ - Variety

·6d ago

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email
Photo credit : Mike Love, John Stamos at the 54th Annual Songwriters Hall of Fame Induction and Awards Gala held at the Marriott Marquis Hotel on June 12, 2025 in New York, New York. (Photo by Stephanie Augello/Variety via Getty Images)

Following many Beach Boys fans and followers expressing concern for Mike Love after seeing footage from the group’s Saturday night show in Cincinnati, John Stamos has stepped in with a statement acknowledging that Love is in poor health as they are doing these shows and suggesting that his longtime friend’s time on stage may be nearing an end.

“I’ve played with Mike for 41 years. I never imagined how deeply it would affect me to see someone larger than life face something so human and fragile,” Stamos said in his Instagram post, managing expectations on his way to performing with the Beach Boys at a show scheduled for Sunday at Nashville’s Ryman Auditorium.

This article is an excerpt. To read the full content, visit the original source. Variety

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patients - Medical Xpress

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Medical Xpress·

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Medical Xpress·

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·